Stage is set for our #OSECompute showcase tonight hearing from some of our incredible #DeepTech portfolio companies Quantum Motion Technologies @OxfordQCircuits PQShield ORCA Computing Salience Labs Oxford Ionics #Fractile

📣 2023 was a productive year for OSE and we've captured it all in our year in review below!

oxfordscienceenterprises.com/highlights/2023

Excited to announce our investment in AlveoGene, a company launched to develop unique inhaled gene therapies for people suffering from rare respiratory disorders.

Full announcement details: shorturl.at/pAP16

📢 A huge welcome to our new CEO Ed Bussey and Jack Edmonson, who joins in the newly created chief Investment Officer role today!

Full announcement details below ⬇️
oxfordscienceenterprises.com/news/oxford-sc…

Huge congrats to the team at Ultromics 👏

Our portfolio company FluoRok on their breakthrough method in producing fluorochemicals in a safer and more sustainable way:

Congratulations Prolific on your latest fundraising round 👏 we're proud to back such an incredible team!

We're excited to back the incredible team FluoRok 👏

Ground-breaking company Beacon Therapeutics launches today with an impressive £96 million. Led by @Sincona, together with funding from Oxford Science Enterprises and University of Oxford the company will aim to restore vision for patients with rare retinal diseases. Read on👇
innovation.ox.ac.uk/news/beacon-th…

Oxfordshire’s #InnovationEngine2023 report published this week by Advanced Oxford and Elsevier calls for action to address the challenges that could hinder growth of the #science & #research sector in #Oxfordshire and sets out 6 recommendations: bit.ly/OIEreport

Our team is collaborating with PHTA Ltd to help early-stage companies continue to scale through access to lab space 🚀

Learn how virtual reality is transforming the field of #mentalhealth treatment globally via our portfolio company @BehaVR_al

Full story: oxford.shorthandstories.com/innovation-vir…

📣Congratulations to our portfolio company OMass Therapeutics for raising an additional £10 million in a Series B extension and appointing Jim Geraghty as chairman of its board of directors.

Full details ⬇️
bit.ly/42XJtjR

Our portfolio company Oxford Flow is celebrating four years of continual operation of their innovative control valves 👏

A huge congratulations to our portfolio company Ultromics for gaining FDA Breakthrough Device Designation for the company's AI-enhanced platform detecting heart failure👏

⬇️ find out more
prnewswire.com/news-releases/…

✍️Our team contributed to a newly launched guide on best practises to turn leading academic research into transformational businesses that will take on the world's challenges and drive economic growth.

Full details below ⬇️

Congrats to the team at OMass Therapeutics for announcing a new flagship site at ARC Oxford Campus and the appointment of a VP of Immunology to support the company's next stage of growth 🚀

Full details ⬇️⬇️
omass.com/2023/04/19/oma…

Congratulations to our portfolio company Caristo Diagnostics on their $16M Series A raise 👏

A brilliant listen to our Pro-Vice-Chancellor for #Innovation University of Oxford speaking with Perspectum and Oxfordshire LEP (OxLEP) about why Oxfordshire is a powerhouse for #innovation

📣Congratulations to our #lifescience portfolio company Grey Wolf Therapeutics on the successful first patient dose in a clinical trial to evaluate their first-in-class ERAP1 inhibitor in patients with advanced solid cancers.

⬇️Full details: greywolftherapeutics.com/grey-wolf-ther…